Cargando…

Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway

Cardiorenal syndrome type 3 (CRS-3) is damage to the heart following acute kidney injury (AKI). Although many experiments have found that inflammation, oxidative stress, and cardiomyocyte death are involved in cardiomyocyte pathophysiological alterations during CRS-3, they lack a non-bias analysis t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jin, Sun, Xuefeng, Wang, Xu, Cui, Shaoyuan, Liu, Ran, Liu, Jiaona, Fu, Bo, Gong, Ming, Wang, Conghui, Shi, Yushen, Chen, Qianqian, Cai, Guangyan, Chen, Xiangmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019825/
https://www.ncbi.nlm.nih.gov/pubmed/33829014
http://dx.doi.org/10.3389/fcell.2021.630412
_version_ 1783674454900998144
author Wang, Jin
Sun, Xuefeng
Wang, Xu
Cui, Shaoyuan
Liu, Ran
Liu, Jiaona
Fu, Bo
Gong, Ming
Wang, Conghui
Shi, Yushen
Chen, Qianqian
Cai, Guangyan
Chen, Xiangmei
author_facet Wang, Jin
Sun, Xuefeng
Wang, Xu
Cui, Shaoyuan
Liu, Ran
Liu, Jiaona
Fu, Bo
Gong, Ming
Wang, Conghui
Shi, Yushen
Chen, Qianqian
Cai, Guangyan
Chen, Xiangmei
author_sort Wang, Jin
collection PubMed
description Cardiorenal syndrome type 3 (CRS-3) is damage to the heart following acute kidney injury (AKI). Although many experiments have found that inflammation, oxidative stress, and cardiomyocyte death are involved in cardiomyocyte pathophysiological alterations during CRS-3, they lack a non-bias analysis to figure out the primary mediator of cardiac dysfunction. Herein proteomic analysis was operated in CRS-3 and growth factor receptor-bound protein 2 (Grb2) was identified as a regulator involving AKI-related myocardial damage. Increased Grb2 was associated with cardiac diastolic dysfunction and mitochondrial bioenergetics impairment; these pathological changes could be reversed through the administration of a Grb2-specific inhibitor during AKI. Molecular investigation illustrated that augmented Grb2 promoted cardiomyocyte mitochondrial metabolism disorder through inhibiting the Akt/mTOR signaling pathway. Besides that, Mouse Inflammation Array Q1 further identified IL-6 as the upstream stimulator of Grb2 upregulation after AKI. Exogenous administration of IL-6 induced cardiomyocyte damage and mitochondrial bioenergetics impairment, whereas these effects were nullified in cardiomyocytes pretreated with Grb2 inhibitor. Our results altogether identify CRS-3 to be caused by the upregulations of IL-6/Grb2 which contribute to cardiac dysfunction through inhibiting the Akt/mTOR signaling pathway and inducing cardiomyocyte mitochondrial bioenergetics impairment. This finding provides a potential target for the clinical treatment of patients with CRS-3.
format Online
Article
Text
id pubmed-8019825
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80198252021-04-06 Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway Wang, Jin Sun, Xuefeng Wang, Xu Cui, Shaoyuan Liu, Ran Liu, Jiaona Fu, Bo Gong, Ming Wang, Conghui Shi, Yushen Chen, Qianqian Cai, Guangyan Chen, Xiangmei Front Cell Dev Biol Cell and Developmental Biology Cardiorenal syndrome type 3 (CRS-3) is damage to the heart following acute kidney injury (AKI). Although many experiments have found that inflammation, oxidative stress, and cardiomyocyte death are involved in cardiomyocyte pathophysiological alterations during CRS-3, they lack a non-bias analysis to figure out the primary mediator of cardiac dysfunction. Herein proteomic analysis was operated in CRS-3 and growth factor receptor-bound protein 2 (Grb2) was identified as a regulator involving AKI-related myocardial damage. Increased Grb2 was associated with cardiac diastolic dysfunction and mitochondrial bioenergetics impairment; these pathological changes could be reversed through the administration of a Grb2-specific inhibitor during AKI. Molecular investigation illustrated that augmented Grb2 promoted cardiomyocyte mitochondrial metabolism disorder through inhibiting the Akt/mTOR signaling pathway. Besides that, Mouse Inflammation Array Q1 further identified IL-6 as the upstream stimulator of Grb2 upregulation after AKI. Exogenous administration of IL-6 induced cardiomyocyte damage and mitochondrial bioenergetics impairment, whereas these effects were nullified in cardiomyocytes pretreated with Grb2 inhibitor. Our results altogether identify CRS-3 to be caused by the upregulations of IL-6/Grb2 which contribute to cardiac dysfunction through inhibiting the Akt/mTOR signaling pathway and inducing cardiomyocyte mitochondrial bioenergetics impairment. This finding provides a potential target for the clinical treatment of patients with CRS-3. Frontiers Media S.A. 2021-03-22 /pmc/articles/PMC8019825/ /pubmed/33829014 http://dx.doi.org/10.3389/fcell.2021.630412 Text en Copyright © 2021 Wang, Sun, Wang, Cui, Liu, Liu, Fu, Gong, Wang, Shi, Chen, Cai and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Wang, Jin
Sun, Xuefeng
Wang, Xu
Cui, Shaoyuan
Liu, Ran
Liu, Jiaona
Fu, Bo
Gong, Ming
Wang, Conghui
Shi, Yushen
Chen, Qianqian
Cai, Guangyan
Chen, Xiangmei
Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway
title Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway
title_full Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway
title_fullStr Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway
title_full_unstemmed Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway
title_short Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway
title_sort grb2 induces cardiorenal syndrome type 3: roles of il-6, cardiomyocyte bioenergetics, and akt/mtor pathway
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019825/
https://www.ncbi.nlm.nih.gov/pubmed/33829014
http://dx.doi.org/10.3389/fcell.2021.630412
work_keys_str_mv AT wangjin grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT sunxuefeng grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT wangxu grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT cuishaoyuan grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT liuran grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT liujiaona grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT fubo grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT gongming grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT wangconghui grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT shiyushen grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT chenqianqian grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT caiguangyan grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway
AT chenxiangmei grb2inducescardiorenalsyndrometype3rolesofil6cardiomyocytebioenergeticsandaktmtorpathway